Furthermore, antiandrogen therapy with 5αRI lowers PSA levels in benign prostatic hyperplasia or low-grade PC but shows less PSA-lowering effects in high-grade PC (23,24). The gene discussed is KLK3; the disease is benign prostatic hyperplasia.